Valuation: CSL Limited

Market Cap 58.62B 50.79B 47.93B 43.49B 81.58B 5,618B 82.17B 572B 221B 2,850B 220B 215B 9,061B P/E 2027 *
20.1x
P/E 2028 * 18.2x
Enterprise Value 67.8B 58.75B 55.44B 50.29B 94.35B 6,498B 95.03B 662B 255B 3,296B 255B 249B 10,480B EV / Sales 2027 *
4.3x
EV / Sales 2028 * 4.13x
Free-Float
99.97%
Yield 2027 *
2.45%
Yield 2028 * 2.6%
1 week+0.40%
Current month+0.69%
1 month+26.89%
3 months+59.58%
6 months+21.49%
Current year+6.20%
1 week 101.6
Extreme 101.6
108.96
1 month 83
Extreme 83
108.96
3 years 56
Extreme 56
192.12
5 years 56
Extreme 56
205.95
10 years 56
Extreme 56
212.6
Manager TitleAgeSince
Chief Executive Officer 63 10/02/2026
Director of Finance/CFO 52 06/10/2025
Chief Operating Officer - 30/04/2025
Director TitleAgeSince
Director/Board Member 72 16/10/2018
Director/Board Member 70 01/02/2011
Director/Board Member 71 08/12/2019
Change 5-day change 1-year change 3-year change Capi.($)
+1.73%-4.93%-10.96%-34.73% 58.62B
+1.57%-4.11%+41.74%-4.64% 79.26B
+1.89%+0.78%+523.95%+30.03% 58.56B
+1.57%-0.31%-14.78%-34.90% 58.62B
+0.35%-3.14%-11.03%+26.34% 48.75B
-0.24%+1.50%+2.19%+149.41% 46.32B
+0.10%-1.57%+50.05%-15.20% 32.12B
+0.59%-3.60%+47.04%+92.49% 24.77B
-1.91%-5.19%-0.63%+142.35% 21.5B
-0.40%-2.19%+63.74%+99.38% 15.97B
Average +0.12%-1.72%+69.13%+45.05% 42.87B
Weighted average by Cap. +0.41%-1.65%+80.60%+26.92%

Financials

2027 *2028 *
Net sales 15.76B 13.66B 12.89B 11.69B 21.93B 1,511B 22.09B 154B 59.32B 766B 59.2B 57.9B 2,436B 16.31B 14.13B 13.34B 12.1B 22.7B 1,563B 22.86B 159B 61.38B 793B 61.26B 59.91B 2,521B
Net income 2.84B 2.46B 2.32B 2.1B 3.95B 272B 3.98B 27.71B 10.68B 138B 10.66B 10.42B 439B 3.17B 2.74B 2.59B 2.35B 4.41B 303B 4.44B 30.92B 11.91B 154B 11.89B 11.63B 489B
Net Debt 9.18B 7.95B 7.5B 6.81B 12.77B 880B 12.86B 89.63B 34.54B 446B 34.47B 33.71B 1,419B 8.81B 7.63B 7.2B 6.53B 12.25B 844B 12.34B 86B 33.14B 428B 33.07B 32.34B 1,361B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
-
Date Price Change
15/09/26 107.14 +1.73%
14/09/26 €105.32 +1.90%
11/09/26 €103.36 +0.10%
10/09/26 €103.26 -1.79%
09/09/26 €105.14 -2.65%
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
122.40USD
Average target price
123.23USD
Spread / Average Target
+0.68%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!